MedTrace Logo

Analysis of the Real-world Prescription Pattern of Palbociclib Combination Therapy With Aromatase Inhibitor as a First Line Therapy in Metastatic Breast Cancer Patients Using the National Health Insurance Claims Data in South Korea

NCT05132101 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2758

Last updated 2025-06-19

No results posted yet for this study

Summary

The objective of this study is to evaluate the real-world prescription patterns of Palbociclib in breast cancer (BC) patients who were treated with Palbociclib in combination with AI as a 1st line of therapy using the national health insurance claims data in South Korea.

Conditions

Interventions

DRUG

Patients who received Palbociclib as first line therapy in MBC setting

Patients who received Palbociclib as first line therapy in MBC setting

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-20
Primary Completion
2022-03-14
Completion
2022-03-14

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05132101 on ClinicalTrials.gov